Ikena Oncology (NASDAQ:IKNA - Get Free Report) announced its earnings results on Thursday, May 8th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.03, Zacks reports.
Ikena Oncology Stock Up 1.9%
IKNA traded up $0.02 during trading hours on Thursday, reaching $1.10. 33,412 shares of the company's stock traded hands, compared to its average volume of 167,522. The firm has a 50-day moving average price of $1.21 and a 200 day moving average price of $1.45. The firm has a market capitalization of $53.08 million, a PE ratio of -0.89 and a beta of 0.47. Ikena Oncology has a 52-week low of $0.97 and a 52-week high of $1.94.
Ikena Oncology Company Profile
(
Get Free Report)
Ikena Oncology, Inc operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway.
Featured Stories
Before you consider Ikena Oncology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ikena Oncology wasn't on the list.
While Ikena Oncology currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
